Japan · Delayed Price · Currency is JPY RaQualia Pharma Company Description
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide.
Its human products portfolio includes tegoprazan for gastroesophageal reflux disease; and grapiprant for cancer and pain management; RQ-00000008 for the treatment of osteoarthritis autoimmune disorders; RQ-00000010 to treat gastroparesis.
The company also provides veterinary products, such as capromorelin to treat anorexia in dogs and weight management in cats; grapiprant for osteoarthritis in dogs; RQ-00000008 to treat osteoarthritis and others; RQ-00317076 for pain; and RQ-00000010 for gut motility disorders, gastroparesis, functional dyspepsia, and chronic constipation.
In addition, it provides RQ-00433412 for constipation, and cancer-related anorexia/cachexia syndrome; RQ-00000009 to treat alzheimer's; RQ-00466479, RQ-00350215, and RQ-00434739 to treat chronic pain; RQ-00310941 to treat D-IBS, IBD-remission stage symptoms; RQ-00201894 for gastroparesis, functional dyspepsia, and post-operative ileus; tamibarotene to treat higher-risk myelodysplastic syndrome and acute myeloid leukemia; and FIM-001 for cancer.
The company was incorporated in 2008 and is headquartered in Nagoya, Japan.
| Country | Japan |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Masaki Sudo |
Contact Details
Address: Meieki Southside Square Nagoya, 450-0003 Japan | |
| Phone | 81 52 446 6100 |
| Website | raqualia.com |
Stock Details
| Ticker Symbol | 4579 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3967150008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Masaki Sudo | Chief Executive Officer |
| Hidefumi Sugiyama | Chief Financial Officer |